BioCryst Pharma (BCRX) PT Raised to $18 at Cowen

May 6, 2021 10:19 AM EDT
Get Alerts BCRX Hot Sheet
Price: $15.89 -2.87%

Rating Summary:
    15 Buy, 5 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 15 | Down: 13 | New: 24
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Cowen analyst Ken Cacciatore raised the price target on BioCryst Pharma (NASDAQ: BCRX) to $18.00 (from $16.00) while maintaining an Outperform rating.

The analyst commented, "BioCryst reported strong first full quarter Orladeyo sales, and we view the initial launch metrics of meaningful patient switches (vs. clinical trial conversion) as particularly encouraging. Management is clearly executing. Additionally, our early clinician feedback is nicely supportive, and we continue to believe Orladeyo could exceed $500MM+, while the pipeline could meaningfully add. Buy here."

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change

Related Entities

Cowen & Co